Lazard Asset Management
CNTA

Lazard Asset Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Lazard Asset Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-131,351
Closed -$1.73M – 1907
2025
Q2 		$1.73M Buy
131,351
+57,633
+78% +$730K ﹤0.01% 1061
2025
Q1 		$1.06M Buy
73,718
+529
+0.7% +$8.66K ﹤0.01% 1196
2024
Q4 		$1.23M Buy
+73,189
New +$1.21M ﹤0.01% 1066

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Lazard Asset Management's CNTA Position: Q3 2025 in Review

Lazard Asset Management sold out of Centessa Pharmaceuticals (CNTA) in Q3 2025, closing a stake of 131,351 shares — an estimated $1.73M sold.

Lazard Asset Management first reported a position in CNTA in Q4 2024 and held it in 3 quarters. The position peaked at $1.73M in Q2 2025. 125 funds tracked by Wall St. Rank hold CNTA as of Q3 2025.

  • Lazard Asset Management reported no remaining Centessa Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 131,351 Centessa Pharmaceuticals shares in Q3 2025, an estimated $1.73M.
  • Lazard Asset Management first reported a position in Centessa Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Lazard Asset Management's Centessa Pharmaceuticals position peaked at $1.73M in Q2 2025.
  • 125 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.